Everfront Biotech Inc.

China Medical University

Gwo Xi Stem Cell Applied Technology Co., Ltd.

Industrial Technology Research Institute

Academia Sinica

National Dong Hwa University

Buddhist Tzu Chi General Hospital

Neuralstem, Inc.

Taiwan Mitochondrion Applied Technology Co., Ltd.

Stemcyte, Inc.

Tzu Chi Buddhist General Hospital

Hawking Biological Technology Co., Ltd.

Ejia Biotechnology Co., Ltd.

Taiwan Mitochondrion Applied Technology

Lin, Shinn-zong

Shinn-Zong Lin

Horng-Jyh Harn

Tzyy-Wen Chiou

Woei-Cherng Shyu

Po-Cheng Lin

Hong-Lin Su

Hung Li

Shih-Ping Liu

Ming-Hsi Chuang

Hsiao-Jung Wang

Ru-Huei Fu

Yu-Ting Huang

Mean-Jue Tung

Shiaw-Min Hwang

Yi-Shan Lin

Li-Kou Chen

Ping-Shan Lai

Kuo-Wei Hsueh

Huai-En Lu

Chia-Yu Chang

Mao-Hsuan Huang

Ssu-Yin Yen

Hsin-Hsin Shen

Rung-Ywan Tsai

Karl K Johe

Yuan-Chin Lee

Wen-Liang Chang

Han-Chung Cheng

Wei-Lin Yu

Chi-Tang Tu

Cheng-Han Wu

Sheng-Feng Tsai

Hsiu-Chin Lee

Hsiang-Ming Huang

Hung-Chuan Pan

Li-Fu Chang

Jiann-Kuan Luo

Jeanne Hsieh

Yeung-Leung Cheng

Kang-Yun Lu

Nu-Man Tsai

Demeral David Liu

Hen-Yi Chu

Yu-Han Chiu

Yi-Wen Chou

Hong-Meng Chuang

Yi-Chun Lin

Karthyayani Rajamani

Chun-Wei Chuang

Applications of butylidenephthalide (BP), comprising the use of BP in providing a kit for promoting differentiation of stem cells into brown adipose cells, and the use of BP in preparing a medicament, wherein the medicament is used for inhibiting the accumulation of white adipose cells, promoting the conversion of white adipose cells into brown adipose cells, inhibiting weight gain and/or reducing the content of triglycerides, glucose, and total cholesterol in blood.

Applications of butylidenephthalide

This present invention provides a method for continuously maintaining growth of a motor neuron progenitor cell and a pharmaceutical composition. Wherein, the method for continuously maintaining growth of a motor neuron progenitor cell is to culture the motor neuron progenitor cell in an environment which is constructed by the olfactory ensheathing cells to make the motor neuron progenitor cell sustain the ability to self-replicate and to be induced for differentiating into mature neuron, and therefore to elaborate the effect to protect the motor neuron. The motor neuron progenitor cell produced from the method disclosed in this present invention can be an effective ingredient of the pharmaceutical composition for treating related diseases of damaged motor neuron.

Method and pharmaceutical composition for continuously maintaining growth of a motor neuron progenitor cell

The invention relates to the treatment of chronic stroke, traumatic brain injury, and neurodegenerative disorders using umbilical cord blood cells.

Treatment of brain damage using umbilical cord blood cells

A method for the anti-senescence of and/or rejuvenating a stem cell is provided. The method comprising treating the stem cell with trans-cinnamaldehyde (TC). A kit is also provided. The kit comprising (1) a first part, comprising a stem cell; (2) a second part, comprising TC; and (3) a culture medium of the stem cell, placed in at least one of the first part, the second part, and a third part. In addition, a method for stem cell therapy is provided. The method comprising administering to a subject in need an effective amount of a stem cell, wherein the stem cell has been treated with TC before being administered.

Method for the anti-senescence of and/or rejuvenating stem cells

A method for providing an increased expression of at least one of telomerase, brain-derived neurotrophic factor (BDNF), stromal cell-derived factor-1 (SDF1), CXC chemokine receptor 4 (CXCR4), and an immune regulatory factor of a stem cell in a subject is provided. The method comprises simultaneously or separately administering to the subject an effective amount of (a) a phthalide and (b) a stem cell.

Method for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, CXC chemokine receptor 4, and/or immune regulatory factor of stem cell

A method for decreasing the incidence rate and/or recurrent rate of cancer is provided. The method comprises administering to a subject in need an effective amount of butylidenephthalide (BP).

Uses of butylidenephthalide

A method for at least one of activating autoimmune system and treating cancer is provided. The method comprises administering to a subject in need an effective amount of Z-butylidenephthalide and an effective amount of mononuclear cells.

Use of Z-butylidenephthalide in activating autoimmune system

The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the &#x3b2;-amyloid protein (A&#x3b2;) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of A&#x3b2; in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered. Furthermore, the method for preparing a pharmaceutical composition containing Bdph comprises preparing the pharmaceutical composition through an organic synthesis reaction, wherein the Bdph is coated with a polymeric material such as F127 by covalent bonding of the polymeric material with the Bdph, thereby achieving the effect of reducing the cytotoxicity of the pharmaceutical composition for an organism.

Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same

A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (BMP-7), stromal cell-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), C-X-C chemokine receptor type-4 (CXCR4), brain-derived neurotrophic factor (BDNF), and/or interleukin-17 (IL-17), and wherein the extract is especially suitable for repairing skin aging.

Mesenchymal stem cell extract and its use

A cell for treating neurodegenerative disease treated withextract is provided. The pharmaceutical composition comprises the cell for treating neurodegenerative disease and can significantly increase and recover the number of dopaminergic neurons to achieve the goal for treating neurodegenerative disease.

Isolated adipose-derived mesenchymal stem cells treated with angelica extract or butylidenephthalide, and wherein the cells have an increased mitochondrial membrane potential and a decreased level of IL-8, and methods for treating parkinson's disease

The present invention relates to a method of delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis, comprising administering to a subject in need an effective amount of an active ingredient selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), and combinations thereof: wherein,

Method for delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis

Disclosed is the use of an active ingredient in the manufacture of a medicament, wherein the active ingredient is selected from the group consisting of butylidenephthalide (BP), a pharmaceutically acceptable salt of butylidenephthalide, and combinations thereof, and wherein the medicament is used for the prevention and/or treatment of oral submucous fibrosis (OSF) and may be used in the form of an injection lozenge, oral solution, or smearing preparation.

Use of butylidenephthalide

A method for treating and/or delaying the degeneration of Purkinje cells in a subject is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a medicament, wherein the medicament comprises a phthalide selected from the group consisting of n-butylidenephthalide (BP), a metabolic precursor of BP, a pharmaceutically acceptable salt of a metabolic precursor of BP, a pharmaceutically acceptable ester of a metabolic precursor of BP, and combinations thereof.

Method for treating and/or delaying the degeneration of Purkinje cells

A method for treating pancreatic cancer is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises (Z)-butylidenephthalide and is substantially free of (E)-butylidenephthalide.

Method for treating pancreatic cancer

Growing community of inventors

Taichung, Taiwan

Shinn-Zong Lin